Rib-X℠ is developing broad spectrum antibiotics with superior coverage, safety and convenience to deliver new standards of care for patients with serious infections. More

12.15.11 - Rib-X Reports Positive Top-Line Data from Phase 2b Study of Delafloxacin in Patients with Acute Bacterial Skin and Skin Structure Infections Read More 

11.28.11 - Rib-X Pharmaceuticals Files Registration Statement For Proposed Initial Public Offering Read More

10.21.11 - Rib-X Pharmaceuticals' RX-04 Program Yields Compounds with In Vitro Potency Against Multi-drug Resistant P. aeruginosa Read More